Clinical Trial Solutions

Invicro’s clinical capabilities span from early phase, first-in-human through late phase and post-approval studies. We focus on studies containing imaging and pathology-based endpoints requiring robust, independent assessments to ascertain drug efficacy.

Our imaging core lab and CAP/CLIA lab-based pathology services solutions support various therapeutic areas including oncology, immuno-oncology, neurology (CNS), cardiovascular, musculoskeletal and gastrointestinal. Our experience comes from years of successful execution of Phase II-IV studies across the development spectrum led by a leadership team with an average of 25 years of industry experience.

Contact us


As a leading imaging and pathology services provider, we acquire, store, analyze, and report data needed to help biopharmaceutical partners make decisions about their drug development programs. Invicro supports a broad range of modalities to evaluate key clinical endpoints in clinical studies including:

  • CT
  • MRI
  • PET
  • NM bone scan
  • Echo
  • X-ray
  • Photography
  • Ultrasound
  • Core histology
  • Multiplex Immunohistochemistry (IHC)
  • Multiplex Immunofluorescence (IF)
  • Quanticell™ High sensitivity Immunohistochemistry (IHC)
  • RNAScope® ISH
  • BaseScope™ ISH
  • Additional Modalities Available